Lumos gets cash to expand reach of respiratory test

By LabPulse.com staff writers

February 6, 2020 -- Lumos Diagnostics has received $1.5 million in series A funding from parent company Planet Innovation of Box Hill, Victoria, Australia.

Lumos is a Planet Innovation spin-off that merged with RPS Diagnostics in May 2019. The company plans to use the funding to support international market expansion of its FebriDx point-of-care (POC) respiratory infection test, as well as a pivotal trial to support approval of the product by the U.S. Food and Drug Administration (FDA).

FebriDx helps differentiate between viral and bacterial acute respiratory infections through a finger-stick blood sample, which can help limit unnecessary antibiotic prescriptions for viral conditions, according the company.

To date, the test has received market clearance in Canada, Europe, Saudi Arabia, Singapore, and Pakistan.

Fusion Genomics secures $1M U.S. to study respiratory infections panel
Canadian diagnostics developer Fusion Genomics has received a $1.2 million Canadian ($1 million U.S.) grant from the CQDM Quantum Leap program for...
Applied BioCode respiratory panel gets U.S. OK
Applied BioCode's Respiratory Pathogen Panel designed for use with its BioCode MDx-3000 molecular system has received 510(k) clearance from the U.S. Food...
Why blood cultures must come first in suspected sepsis
Patients suspected of having sepsis must get blood cultures prior to antibiotic therapy, in line with national guidelines, according to a study published...
T2Bacteria panel proves itself, but will hospitals buy in?
The T2Bacteria panel was accurate and fast for detecting five common kinds of bacteria in the blood in a multicenter study published May 13 in the Annals...

Copyright © 2020 LabPulse.com

Last Updated np 2/5/2020 3:35:28 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current